Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401152 | 0.85 | MAPT (0.42) | SORDKDM4ENPC1RAB9AHRH3 | |
| SCHEMBL31396039 | 0.84 | MAPT (0.45) | SORDKDM4EDRD4NPC1RAB9A | |
| SCHEMBL23706098 | 0.83 | MAP4K4 (0.43) | KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL31395896 | 0.81 | NPC1 (0.39) | SORDKDM4ENPC1RAB9ASLC6A7 | |
| SCHEMBL31401341 | 0.75 | CHRNB2 (0.43) | KDM4EL3MBTL1NPC1RAB9AHRH3 | |
| SCHEMBL31401410 | 0.74 | PDE10A (0.55) | — | |
| SCHEMBL26970022 | 0.72 | PIM1 (0.37) | — | |
| SCHEMBL30895900 | 0.71 | HTR3A (0.43) | KDM4EHRH3ALDH1A1 | |
| SCHEMBL31401353 | 0.71 | HDAC1 (0.51) | KDM4ELMNANPC1RAB9AHRH3 | |
| SCHEMBL3137995 | 0.66 | HRH3 (0.52) | SORDKDM4EDRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |